Chow, Andrew http://orcid.org/0000-0003-1151-2450
Perica, Karlo
Klebanoff, Christopher A. http://orcid.org/0000-0001-9645-3896
Wolchok, Jedd D. http://orcid.org/0000-0001-6718-2222
Article History
Accepted: 6 September 2022
First Online: 10 October 2022
Competing interests
: C.A.K. has received research grant support from Kite/Gilead and Intima Bioscience, is on the scientific and/or clinical advisory boards of Achilles Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Catamaran Bio, Obsidian Therapeutics and T-knife, and has provided consulting services for Bristol Myers Squibb, PACT Pharma and Roche/Genentech. C.A.K. is also a co-inventor on patent-licensed applications related to T cell receptors targeting public neoantigens unrelated to the current work. J.D.W. is a consultant for Amgen, Apricity, Ascentage Pharma, Astellas, AstraZeneca, Bicara Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, CellCarta, Chugai, Daiichi Sankyo, Dragonfly, Georgiamune, Idera, Imvaq, Larkspur, Maverick Therapeutics, Merck, Psioxus, Recepta, Tizona, Trishula, Sellas, Surface Oncology, Werewolf Therapeutics. J.D.W receives grant/research support from Bristol Myers Squibb and Sephora. J.D.W has equity in Apricity, Arsenal IO, Ascentage, Beigene, Imvaq, Linneaus, Georgiamune, Maverick, Tizona Pharmaceuticals and Trieza. J.D.W is a co-inventor on the following patent applications: xenogeneic (canine) DNA vaccines, myeloid-derived suppressor cell (MDSC) assay, anti-PD-1 antibody, anti-CTLA4 antibodies, anti-GITR antibodies and methods of use thereof, Newcastle disease viruses for cancer therapy, and prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment. A.C. and K.P. declare no competing interests.